Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Woods LT, Ajit D, Camden JM, Erb L, Weisman GA.

Neuropharmacology. 2016 May;104:169-79. doi: 10.1016/j.neuropharm.2015.10.031. Epub 2015 Oct 28. Review.

PMID:
26519903
2.

Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.

Li S, Hou H, Mori T, Sawmiller D, Smith A, Tian J, Wang Y, Giunta B, Sanberg PR, Zhang S, Tan J.

Sci Rep. 2015 Jun 19;5:11322. doi: 10.1038/srep11322.

3.

DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease.

Jackson HM, Onos KD, Pepper KW, Graham LC, Akeson EC, Byers C, Reinholdt LG, Frankel WN, Howell GR.

PLoS One. 2015 May 1;10(5):e0125897. doi: 10.1371/journal.pone.0125897. eCollection 2015.

4.

The γ-secretase complex: from structure to function.

Zhang X, Li Y, Xu H, Zhang YW.

Front Cell Neurosci. 2014 Dec 11;8:427. doi: 10.3389/fncel.2014.00427. eCollection 2014. Review.

5.

The impact of human and mouse differences in NOS2 gene expression on the brain's redox and immune environment.

Hoos MD, Vitek MP, Ridnour LA, Wilson J, Jansen M, Everhart A, Wink DA, Colton CA.

Mol Neurodegener. 2014 Nov 17;9:50. doi: 10.1186/1750-1326-9-50.

6.

Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model.

Wu Z, Guo Z, Gearing M, Chen G.

Nat Commun. 2014 Jun 13;5:4159. doi: 10.1038/ncomms5159. Erratum in: Nat Commun. 2014;5:4810.

7.

Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators.

Qin J, Zhou W, Huang X, Dhondi P, Palani A, Aslanian R, Zhu Z, Greenlee W, Cohen-Williams M, Jones N, Hyde L, Zhang L.

ACS Med Chem Lett. 2011 Mar 29;2(6):471-6. doi: 10.1021/ml2000438. eCollection 2011 Jun 9.

8.

Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.

Agis-Torres A, Sölhuber M, Fernandez M, Sanchez-Montero JM.

Curr Neuropharmacol. 2014 Jan;12(1):2-36. doi: 10.2174/1570159X113116660047.

9.

Disease-modifying drugs in Alzheimer's disease.

Ghezzi L, Scarpini E, Galimberti D.

Drug Des Devel Ther. 2013 Dec 6;7:1471-8. doi: 10.2147/DDDT.S41431. Review.

10.

Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease.

Jackson HM, Soto I, Graham LC, Carter GW, Howell GR.

BMC Genomics. 2013 Nov 25;14:831. doi: 10.1186/1471-2164-14-831.

11.

Cognitive health begins at conception: addressing dementia as a lifelong and preventable condition.

Barnett JH, Hachinski V, Blackwell AD.

BMC Med. 2013 Nov 19;11:246. doi: 10.1186/1741-7015-11-246.

12.

Amyloid-β and APP deficiencies cause severe cerebrovascular defects: important work for an old villain.

Luna S, Cameron DJ, Ethell DW.

PLoS One. 2013 Sep 5;8(9):e75052. doi: 10.1371/journal.pone.0075052. eCollection 2013.

13.

γ-Secretase inhibitors and modulators.

Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L.

Biochim Biophys Acta. 2013 Dec;1828(12):2898-907. doi: 10.1016/j.bbamem.2013.06.005. Epub 2013 Jun 17. Review.

14.

Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation.

Hajós M, Morozova E, Siok C, Atchison K, Nolan CE, Riddell D, Kiss T, Hajós-Korcsok E.

Front Pharmacol. 2013 Jun 14;4:72. doi: 10.3389/fphar.2013.00072. eCollection 2013.

16.

Why our patients (and we) need basic science research.

Schor NF.

Neurology. 2013 May 28;80(22):2070-5. doi: 10.1212/WNL.0b013e318294b48a.

17.

γ-Secretase inhibition promotes fibrotic effects of albumin in proximal tubular epithelial cells.

Slattery C, Jang Y, Kruger WA, Hryciw DH, Lee A, Poronnik P.

Br J Pharmacol. 2013 Jul;169(6):1239-51. doi: 10.1111/bph.12214.

18.

Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.

Sivilia S, Lorenzini L, Giuliani A, Gusciglio M, Fernandez M, Baldassarro VA, Mangano C, Ferraro L, Pietrini V, Baroc MF, Viscomi AR, Ottonello S, Villetti G, Imbimbo BP, Calzà L, Giardino L.

BMC Neurosci. 2013 Apr 5;14:44. doi: 10.1186/1471-2202-14-44.

19.

Involvement of presenilin holoprotein upregulation in calcium dyshomeostasis of Alzheimer's disease.

Honarnejad K, Jung CK, Lammich S, Arzberger T, Kretzschmar H, Herms J.

J Cell Mol Med. 2013 Feb;17(2):293-302. doi: 10.1111/jcmm.12008. Epub 2013 Feb 5.

20.

The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.

Hussain I, Fabrègue J, Anderes L, Ousson S, Borlat F, Eligert V, Berger S, Dimitrov M, Alattia JR, Fraering PC, Beher D.

J Biol Chem. 2013 Jan 25;288(4):2521-31. doi: 10.1074/jbc.M112.370924. Epub 2012 Dec 3.

Items per page

Supplemental Content

Write to the Help Desk